◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › O › ONC

BeiGene, Ltd. (ONC) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-11

BeiGene, Ltd. (ONC) operates in the BIOTECHNOLOGY industry and is headquartered in Basel, Switzerland with about 12,000 employees. Its market capitalization is roughly $40 billion. In the fiscal year ended 2025-12-31, ONC reported $5.3B in revenue and $287M in net income.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

Interactive charts & full statements → Open the ONC valuation workbench →

ONC Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$6.1B	$5.3B	$3.8B	$2.5B	$1.4B	$1.2B	$309M	$428M	$198M	$238M	$1M	$9M	$13M	$11M
Gross Profit	$5.4B	$4.7B	$3.2B	$2.1B	$1.1B	$1.0B	$238M	$357M	($509M)	($36M)	($97M)	($49M)	($9M)	($2M)
Gross Margin %	88.9%	87.5%	84.4%	84.5%	79.8%	86.0%	77.1%	83.4%	-257.0%	-14.9%	-9062.0%	-560.7%	-67.7%	-20.8%
Operating Income (EBIT)	$923M	$447M	($568M)	($1.2B)	($1.8B)	($1.4B)	($1.7B)	($960M)	($706M)	($98M)	($117M)	($57M)	($16M)	($5M)
Operating Margin %	15.1%	8.4%	-14.9%	-49.1%	-126.4%	-122.3%	-536.7%	-224.2%	-356.1%	-41.3%	-10940.2%	-643.7%	-120.9%	-49.0%
Net Income	$656M	$287M	($645M)	($882M)	($2.0B)	($1.5B)	($1.6B)	($949M)	($674M)	($93M)	($119M)	($57M)	($18M)	($7M)
Net Margin %	10.7%	5.4%	-16.9%	-35.9%	-141.5%	-123.9%	-526.1%	-221.5%	-339.9%	-39.1%	-11141.8%	-647.7%	-140.2%	-67.2%
EBITDA	$1.2B	$617M	($361M)	($738M)	($1.9B)	($1.4B)	($1.6B)	($941M)	($695M)	($94M)	($115M)	($55M)	($14M)	($3M)
Earnings Per Share (EPS)	$5.69	$2.53	$-6.12	$-8.45	$-19.43	$-15.71	$-19.47	$-15.80	$-12.15	$-2.23	$-3.84	$-1.81	$-0.35	$-1.42
Shares Outstanding (M)	116M	113M	105M	104M	103M	93M	83M	60M	55M	42M	31M	32M	—	5M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ONC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$1.7B	$1.5B	$1.5B	$1.4B	$1.3B	$1.1B	$1.1B	$1.0B
Gross Profit	$1.5B	$1.3B	$1.4B	$1.2B	$1.2B	$952M	$967M	$831M
Gross Margin %	89.8%	88.9%	90.5%	86.1%	87.5%	85.2%	85.8%	83.0%
Operating Income (EBIT)	$325M	$250M	$185M	$163M	$88M	$11M	($79M)	($120M)
Operating Margin %	19.1%	16.5%	12.3%	11.6%	6.7%	1.0%	-7.0%	-12.0%
Net Income	$237M	$227M	$67M	$125M	$94M	$1M	($152M)	($121M)
Net Margin %	13.9%	15.0%	4.4%	8.8%	7.2%	0.1%	-13.5%	-12.1%
EBITDA	$393M	$333M	$249M	$184M	$135M	$61M	($35M)	($27M)
Earnings Per Share (EPS)	$2.05	$1.96	$0.59	$1.09	$0.84	$0.01	$-1.43	$-1.16
Shares Outstanding (M)	116M	116M	113M	115M	113M	111M	106M	105M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ONC Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	$1.7B	$1.1B	($141M)	($1.2B)	($1.5B)	($1.3B)	($1.3B)	($750M)	($548M)	$13M	($90M)	($40M)	($9M)	$4M
Capital Expenditures (CapEx)	$443M	$186M	$529M	$596M	$469M	$315M	$229M	$159M	$141M	$59M	$24M	$5M	$1M	$0M
Free Cash Flow (FCF)	$1.2B	$942M	($670M)	($1.8B)	($2.0B)	($1.6B)	($1.5B)	($909M)	($689M)	($46M)	($113M)	($45M)	($9M)	$4M
FCF Margin %	20.3%	17.6%	-17.6%	-71.3%	-138.8%	-137.2%	-489.7%	-212.2%	-347.4%	-19.3%	-10562.1%	-512.2%	-71.7%	34.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ONC Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$664M	$202M	$417M	$403M	$264M	$44M	$75M	$188M
Capital Expenditures (CapEx)	$68M	$41M	$286M	$48M	$64M	$116M	$92M	$134M
Free Cash Flow (FCF)	$596M	$161M	$131M	$354M	$200M	($72M)	($17M)	$55M
FCF Margin %	34.9%	10.6%	8.8%	25.1%	15.2%	-6.5%	-1.5%	5.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ONC Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$9.2B	$8.2B	$5.9B	$5.8B	$6.4B	$8.5B	$5.6B	$1.6B	$2.2B	$1.0B	$406M	$117M	$54M	$12M
Cash & Cash Equivalents	$5.1B	$4.5B	$2.6B	$3.2B	$3.9B	$4.4B	$1.4B	$618M	$713M	$240M	$88M	$18M	$14M	$4M
Total Liabilities	$4.0B	$3.8B	$2.6B	$2.3B	$2.0B	$2.4B	$1.7B	$634M	$496M	$362M	$53M	$42M	$28M	$49M
Total Debt (Short + Long-Term)	$1.1B	$1.1B	$1.0B	$908M	$562M	$652M	$533M	$11M	$9M	$9M	$0M	$15M	$0M	$20M
Total Shareholders' Equity	$5.2B	$4.4B	$3.3B	$3.5B	$4.4B	$6.1B	$3.9B	$962M	$1.8B	$684M	$353M	($102M)	$26M	($39M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ONC viewer.

Other Companies in BIOTECHNOLOGY

ARGX · argenx NV ADR — $62 billion
RVMD · Revolution Medicines Inc — $41 billion
RPRX · Royalty Pharma Plc — $34 billion
ALNY · Alnylam Pharmaceuticals Inc — $32 billion
ROIV · Roivant Sciences Ltd — $29 billion
INSM · Insmed Inc — $26 billion
BNTX · BioNTech SE — $24 billion
GMAB · Genmab AS — $21 billion

← ONB All “O” companies ONCH →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.